**SCRIPPS RESEARCH**
**INSTITUTIONAL BIOSAFETY COMMITTEE**
**MEETING MINUTES**
**July 09, 2025**

## I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference on July 09, 2025, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

| Committee Members Present | | Committee Members Absent | Others Present |
|---|---|---|---|
| Juan Carlos de la Torre | Michael Bobardt | Jim Gohres | Amy Green |
| Stephen Munday | Smita Chopade | | |
| Elizabeth Ford | Cheryl Andreoli | | |
| Roberto Aiolfi | Elizabeth Montano | | |
| Mychelle Fernandez | Steven Robert Head | | |
| Elyse Walk | Case McNamara | | |
| Raphael Park | | | |

## I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the June 11, 2025 IBC Meeting.

## II. ANNOUNCEMENTS

Three-year renewals of approved IBC protocols will begin in July.

## III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

None.

## IV. CONFLICT OF INTEREST

None.

## V. REVIEW OF PROTOCOLS

**FULL COMMITTEE REVIEW**

**MIGRATIONS**

| | |
|---|---|
| **1. IBC Protocol #:** | **08-14-19-02, Deniz, Ashok** |
| Title of Study: | Single-Molecule and Ensemble Biophysics |
| Department: | ISCB |
| Primary Reviewer: | Mychelle Fernandez |
| Secondary Reviewer: | Steve Head |
| NIH Guidelines: | III-E-1 |
| Biosafety Level: | BSL-1 |
| Animal work: | ☐Yes ☒No |
| Biosafety Inspection: | Not required |
| Training: | Training verified and on record. |

**Summary of Discussion:** A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic

acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

**The following action items were identified as needing to be updated on the protocol:**

**Study Design/Project Description**
A description of biophysical methods is needed.

**Review outcome:** Conditional approval; full approval granted upon completion of the above listed action items.

| | |
|---|---|
| **2. IBC Protocol #:** | **07-14-21-04, Teyton, Luc** |
| Title of Study: | Immune Responses to Bacteria |
| Department: | Immunology & Microbiology |
| Primary Reviewer: | Juan de la Torre |
| Secondary Reviewer: | Beth Ford |
| NIH Guidelines: | III-D-1, III-D-2, III-E |
| Biosafety Level: | BSL-2, ABSL-2 |
| Animal work: | ☒Yes ☐No |
| Biosafety Inspection: | Inspection of IMM 301-302 TBD. |
| Training: | Pending training. |

**Summary of Discussion:** A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

**The following action items were identified as needing to be updated on the protocol:**

**General Information**
The title of the protocol should be changed to reflect the use of both bacteria and viruses.

**Recombinant and Syn NA**
Information about the types of genes that will be expressed using the different expression systems described in the protocol is needed.
Remove BSL-1 from the comments section of the table.

**Vertebrate or Invertebrate Animals**
A description of the source of the different mouse strains is needed.
Indicate that LCMV and H5N1 can potentially infect other mice.

**Human/Non-human Primate Material**
Indicate potential for blood borne pathogens in human blood.

**Exposure Control**
PPE should be listed for ABSL2 work.

**Review outcome:** Conditional approval; full approval granted upon completion of the above listed action items

**AMENDMENT**

| | |
|---|---|
| **1. IBC Protocol #:** | **10-13-21-07, Chanda, Sumit** |
| Title of Study: | Host genetic factors and small molecules that modulate infection and replication of respiratory viruses |
| Department: | Immunology & Microbiology |
| Primary Reviewer: | Roberto Aiolfi |
| Secondary Reviewer: | Raphael Park |
| NIH Guidelines: | III-D-1, III-D-7-b, III-E-1 |
| Biosafety Level: | BSL-2+, ABSL-3 |
| Animal work: | ☒Yes ☐No |
| Biosafety Inspection: | Inspection of IMM 212, Calibr B26 completed on 12/29/23. |
| Training: | Training verified and on record. |

**Summary of Discussion:** A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

**The following action items were identified as needing to be updated on the protocol:**

**General Information**
A brief description of measles virus experimentation is needed.

**Study Design/Project Description**
Provide a detailed description of measles virus experimentation, including the volume and quantity of virus used.

**Exposure Control**
Add measles virus to the vaccinations list under occupational health.

**Review outcome:** Conditional approval; full approval granted upon completion of the above listed action items

**DMR REVIEW**

| | |
|---|---|
| **1. IBC Protocol #:** | **04-13-16-06, Maximov, Anton** |
| Title of Study: | Transcriptional Regulation of Synaptic Plasticity |
| Department: | Neuroscience |
| NIH Guidelines: | III-D-1, III-D-4-a, III-D-4-b |
| Biosafety Level: | BSL-2, ABSL-1 |
| Animal work: | ☒Yes ☐No |
| Training: | Pending training. |
| **REVIEW OUTCOME:** | **Approved.** |

**BIOSAFETY REVIEW**

| | |
|---|---|
| **1. IBC Protocol #:** | **07-13-22-01, Gallay, Philippe** |
| Title of Study: | Respiratory Viruses Studies |
| Department: | Immunology & Microbiology |

NIH Guidelines: III-D-1, III-D-2, III-D-4-b
Biosafety Level: BSL-3, ABSL-2
Animal work: ☒Yes ☐No
Training: Training verified and on record.
**REVIEW OUTCOME: Approved.**

**2. IBC Protocol #: 11-13-24-01, Irvine, Darryl**
Title of Study: Immune engineering studies
Department: Immunology & Microbiology
NIH Guidelines: III-D-1, III-D-2, III-D-4-a, III-D-4-b, III-E-1, III-F-1
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒Yes ☐No
Training: Training verified and on record.
**REVIEW OUTCOME: Approved.**

**VI. ADJOURNMENT**

The next scheduled IBC meeting is **Wednesday, August 13, 2025,** via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled.